



CLN4 disease

CLN4 disease is a condition that primarily affects the nervous system, causing problems with movement and intellectual function that worsen over time. The signs and symptoms of CLN4 disease typically appear around age 30, but they can develop anytime between adolescence and late adulthood.

People with CLN4 disease often develop seizures and uncontrollable muscle jerks (myoclonic epilepsy), a decline in intellectual function (dementia), problems with coordination and balance (ataxia), tremors or other involuntary movements (motor tics), and speech difficulties (dysarthria). The signs and symptoms of CLN4 disease worsen over time, and affected individuals usually survive about 15 years after the disorder begins.

CLN4 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. (The adult forms of NCLs, which includes CLN4 disease, are sometimes known as Kufs disease.) All the NCLs affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation "CLN," meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.

Frequency

CLN4 disease is a rare disorder, but its prevalence is unknown. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

Causes

Mutations in the *DNAJC5* gene cause CLN4 disease. The *DNAJC5* gene provides instructions for making a protein called cysteine string protein alpha (CSP α). This protein is found in the brain, where it plays a role in the transmission of nerve impulses, helping nerve cells communicate with each other. Specifically, CSP α is involved in recycling certain proteins that are involved in nerve impulse transmission by refolding misshapen proteins so that they can be used in additional transmissions.

DNAJC5 gene mutations lead to the production of an altered CSP α protein. The altered protein cannot perform its function, which reduces protein recycling, causing a shortage (deficiency) of functional proteins needed for impulse transmission. Without normal communication between nerve cells, neurological functions are impaired, contributing to the features of CLN4 disease.

CLN4 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes, which are compartments in the cell that digest and recycle materials. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues contributes to the decline of neurological function in CLN4 disease. However, it is unclear how mutations in the *DNAJC5* gene are involved in the buildup of substances in lysosomes.

Inheritance Pattern

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

Some cases of this condition result from new (de novo) mutations in the gene that occur during the formation of reproductive cells (eggs or sperm) in an affected individual's parent or in early embryonic development. These cases occur in people with no history of the disorder in their family.

Other Names for This Condition

- adult neuronal ceroid lipofuscinosis
- ceroid lipofuscinosis, neuronal, 4B, autosomal dominant
- CLN4B
- Parry disease

Diagnosis & Management

Genetic Testing Information

- What is genetic testing?
[/primer/testing/genetic-testing](#)
- Genetic Testing Registry: Neuronal ceroid lipofuscinosis 4B
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C1834207/>

Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov
<https://clinicaltrials.gov/ct2/results?cond=%22Kuf%27s+disease%22+OR+%22Neuronal+Ceroid-Lipofuscinoses%22>

Additional Information & Resources

Health Information from MedlinePlus

- Encyclopedia: Movement--Uncoordinated
<https://medlineplus.gov/ency/article/003198.htm>
- Encyclopedia: Neuronal Ceroid Lipofuscinoses (NCLS)
<https://medlineplus.gov/ency/article/001613.htm>
- Health Topic: Degenerative Nerve Diseases
<https://medlineplus.gov/degenerativenervediseases.html>
- Health Topic: Dementia
<https://medlineplus.gov/dementia.html>
- Health Topic: Epilepsy
<https://medlineplus.gov/epilepsy.html>

Genetic and Rare Diseases Information Center

- Adult neuronal ceroid lipofuscinosis
<https://rarediseases.info.nih.gov/diseases/10973/adult-neuronal-ceroid-lipofuscinosis>

Additional NIH Resources

- National Institute of Neurological Disorders and Stroke: Batten Disease Fact Sheet
<https://www.ninds.nih.gov/Disorders/All-Disorders/Batten-Disease-Information-Page>

Educational Resources

- MalaCards: adult neuronal ceroid lipofuscinosis
https://www.malacards.org/card/adult_neuronal_ceroid_lipofuscinosis
- Merck Manual Consumer Version: Overview of Delirium and Dementia
<https://www.merckmanuals.com/home/brain,-spinal-cord,-and-nerve-disorders/delirium-and-dementia/overview-of-delirium-and-dementia>
- Orphanet: Adult neuronal ceroid lipofuscinosis
https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=79262
- University of Rochester Batten Disease Center
<https://www.urmc.rochester.edu/neurology/batten-disease-center.aspx>

Patient Support and Advocacy Resources

- Batten Disease Family Association
<http://www.bdfa-uk.org.uk/adult-onset-ncls/>
- Batten Disease Support and Research Association
<https://www.bdsra.org/what-is-batten-disease/>

- Beyond Batten Disease Foundation
<https://beyondbatten.org/>
- Family Caregiver Alliance: Dementia
<https://www.caregiver.org/health-issues/dementia>
- Metabolic Support UK
<https://www.metabolicsupportuk.org/>
- National Organization for Rare Disorders (NORD)
<https://rarediseases.org/rare-diseases/kufs-disease/>

Scientific Articles on PubMed

- PubMed
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28%28kufs+disease%5BTIAB%5D%29+OR+%28adult+neuronal+ceroid+lipofuscinosis%5BTIAB%5D%29+OR+%28CLN4+disease%5BTIAB%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D>

Catalog of Genes and Diseases from OMIM

- CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT
<http://omim.org/entry/162350>

Sources for This Summary

- Cadieux-Dion M, Andermann E, Lachance-Touchette P, Ansorge O, Meloche C, Barnabé A, Kuzniecky RI, Andermann F, Faught E, Leonberg S, Damiano JA, Berkovic SF, Rouleau GA, Cossette P. Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease. *Clin Genet*. 2013 Jun;83(6):571-5. doi: 10.1111/cge.12020. Epub 2012 Nov 7.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22978711>
- Henderson MX, Wirak GS, Zhang YQ, Dai F, Ginsberg SD, Dolzhanskaya N, Staropoli JF, Nijssen PC, Lam TT, Roth AF, Davis NG, Dawson G, Velinov M, Chandra SS. Neuronal ceroid lipofuscinosis with DNAJC5/CSP α mutation has PPT1 pathology and exhibit aberrant protein palmitoylation. *Acta Neuropathol*. 2016 Apr;131(4):621-37. doi: 10.1007/s00401-015-1512-2.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/26659577>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791186/>
- Kollmann K, Uusi-Rauva K, Scifo E, Tyynelä J, Jalanko A, Bräulke T. Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. *Biochim Biophys Acta*. 2013 Nov;1832(11):1866-81. doi: 10.1016/j.bbadis.2013.01.019. Epub 2013 Feb 9. Review.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/23402926>
- Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases - clinical perspectives. *Biochim Biophys Acta*. 2013 Nov;1832(11):1801-6. doi: 10.1016/j.bbadis.2013.04.008. Epub 2013 Apr 17.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/23602993>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631127/>

- Smith KR, Dahl HH, Canafoglia L, Andermann E, Damiano J, Morbin M, Bruni AC, Giaccone G, Cossette P, Saftig P, Grötzinger J, Schwake M, Andermann F, Staropoli JF, Sims KB, Mole SE, Franceschetti S, Alexander NA, Cooper JD, Chapman HA, Carpenter S, Berkovic SF, Bahlo M. Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. *Hum Mol Genet.* 2013 Apr 1;22(7):1417-23. doi: 10.1093/hmg/dd558. Epub 2013 Jan 7.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/23297359>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596852/>
- Velinov M, Dolzhanskaya N, Gonzalez M, Powell E, Konidari I, Hulme W, Staropoli JF, Xin W, Wen GY, Barone R, Coppel SH, Sims K, Brown WT, Züchner S. Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. *PLoS One.* 2012;7(1):e29729. doi: 10.1371/journal.pone.0029729. Epub 2012 Jan 3. Erratum in: *PLoS One.* 2012;7(9). doi:10.1371/annotation/26d7eb64-ccd2-41db-b1aa-7cdc8c1eff95.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22235333>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250487/>
- Velinov M, Dolzhanskaya N, Gonzalez M, Powell E, Konidari I, Hulme W, Staropoli JF, Xin W, Wen GY, Barone R, Coppel SH, Sims K, Brown WT, Züchner S. Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. *PLoS One.* 2012;7(1):e29729. doi: 10.1371/journal.pone.0029729. Epub 2012 Jan 3. Erratum in: *PLoS One.* 2012;7(9). doi:10.1371/annotation/26d7eb64-ccd2-41db-b1aa-7cdc8c1eff95.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22235333>
Free article on PubMed Central: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250487/>
- Williams RE, Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. *Neurology.* 2012 Jul 10;79(2):183-91. doi: 10.1212/WNL.0b013e31825f0547.
Citation on PubMed: <https://www.ncbi.nlm.nih.gov/pubmed/22778232>

Reprinted from Genetics Home Reference:
<https://ghr.nlm.nih.gov/condition/cln4-disease>

Reviewed: August 2020

Published: August 17, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services